Proceedings of the National Academy of Sciences · 1976 · 441 citations · 19 references
Life SciencesImmunologyOncologyCancer ImmunologyClinical ImmunologyTumor ImmunologyHistocompatibility AntigensMelanocytic TumorsNonmelanocytic Skin TumorsNonmelanoma Skin CancerTumor AntigensTumor-associated AntigensMalignant Melanocytic TumorsMelanoma DiagnosisMelanoma-associated AntigensTumor Reactivity
We studied how frequently patients with malignant melanoma have specific antibody to cell surface antigens of cultured autologous melanoma cells as demonstrated by mixed hemadsorption assays. Of 35 patients studied over periods ranging from 1 to 36 months with Stage II, III, and IV disease, two showed consistent and high titered reactivity against autologous melanoma cells, two showed less consistent and intermediate reactivity, seven showed sporatic, low titered reactivity, and the remainder were consistently negative. A detailed analysis was carried out with the sera of one patient with sufficiently high titer against autologous melanoma cells. By direct tests and by absorption analysis with a variety of melanoma and nonmelanoma cell lines which included autologous fibroblasts, the antigen could not be demonstrated on any cell type other than the autologous melanoma.
19
Demonstration of antibodies against human malignant melanoma by immunofluorescence.
Morton Dl, Malmgren Ra, Holmes Ec et al. · PubMed · 1968 · 388 citations
Life Sciences, Immunology, Oncology +12
The G (Gross) leukemia antigen.
Lloyd J. Old, Edward A. Boyse, Elisabeth Stockert · PubMed · 1965 · 247 citations
Life Sciences, Immunology, Pathology +13
Matko Cikes, Sten Friberg, George Klein · JNCI Journal of the National Cancer Institute · 1973 · 238 citations
Cell-mediated cytotoxicity for bladder carcinoma: evaluation of a workshop.
Michael A. Bean, Barry R. Bloom, Ronald B. Herberman et al. · PubMed · 1975 · 137 citations